Works matching AU Levy, Yair


Results: 145
    1
    2
    3
    4
    5
    6
    7
    8

    Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 3, p. E83, doi. 10.1002/ajh.26434
    By:
    • Delimpasi, Sosana;
    • Mateos, Maria Victoria;
    • Auner, Holger W.;
    • Gavriatopoulou, Maria;
    • Dimopoulos, Meletios A.;
    • Quach, Hang;
    • Pylypenko, Halyna;
    • Hájek, Roman;
    • Leleu, Xavier;
    • Dolai, Tuphan Kanti;
    • Sinha, Dinesh Kumar;
    • Venner, Christopher P.;
    • Benjamin, Reuben;
    • Garg, Mamta Krishnan;
    • Doronin, Vadim;
    • Levy, Yair;
    • Moreau, Philippe;
    • Chai, Yi;
    • Arazy, Melina;
    • Shah, Jatin
    Publication type:
    Article
    9
    10
    11

    A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.

    Published in:
    2021
    By:
    • Zeidner, Joshua F.;
    • Lin, Tara L.;
    • Vigil, Carlos E.;
    • Fine, Gil;
    • Yair Levy, M.;
    • Nazha, Aziz;
    • Esteve, Jordi;
    • Lee, Daniel J.;
    • Yee, Karen;
    • Dalovisio, Andrew;
    • Wang, Eunice S.;
    • Bergua Burgues, Juan M.;
    • Schriber, Jeffrey;
    • Litzow, Mark R.;
    • Frankfurt, Olga;
    • Castillo, Teresa Bernal Del;
    • Bhatt, Vijaya Raj;
    • Bhatnagar, Bhavana;
    • Mehta, Priyanka;
    • Dillon, Richard
    Publication type:
    Letter
    12
    13
    14
    15

    Why cognitivism?

    Published in:
    Canadian Journal of Philosophy, 2018, v. 48, n. 2, p. 223, doi. 10.1080/00455091.2017.1345207
    By:
    • Levy, Yair
    Publication type:
    Article
    16
    17
    18
    19
    20
    21

    P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST‐IN‐CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2‐MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND‐01 TRIAL.

    Published in:
    HemaSphere, 2022, v. 6, p. 419, doi. 10.1097/01.HS9.0000844968.45342.3d
    By:
    • Martinelli, G.;
    • Santoro, A.;
    • Gambacorti‐Passerini, C.;
    • Vives Polo, S.;
    • Solomon, S. R.;
    • Mukherjee, S.;
    • Lech‐Maranda, E.;
    • Yair Levy, M.;
    • Wierzbowska, A.;
    • Calbacho‐Robles, M.;
    • Marconi, G.;
    • Benedetta Giannini, M.;
    • Cano, I.;
    • Torres Miñana, L.;
    • Acuña‐Cruz, E.;
    • Angelosanto, N.;
    • Galleu, A.;
    • Baldini, S.;
    • Blotta, S.;
    • Ravandi, F.
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.

    Published in:
    Leukemia & Lymphoma, 2020, v. 61, n. 3, p. 650, doi. 10.1080/10428194.2019.1675879
    By:
    • Shah, Neil P.;
    • García-Gutiérrez, Valentín;
    • Jiménez-Velasco, Antonio;
    • Larson, Sarah;
    • Saussele, Susanne;
    • Rea, Delphine;
    • Mahon, François-Xavier;
    • Levy, Moshe Yair;
    • Gómez-Casares, María Teresa;
    • Pane, Fabrizio;
    • Nicolini, Franck-Emmanuel;
    • Mauro, Michael J.;
    • Sy, Oumar;
    • Martin-Regueira, Patricia;
    • Lipton, Jeffrey H.
    Publication type:
    Article
    45
    46
    47
    48
    49
    50